QPS Qualitix sets up Beijing office

- Last updated on GMT

QPS opens China office

Related tags: Clinical trial, Medicine

CRO QPS Qualitix has continued its expansion in Asia with a new office in China.

The office in Beijing's Chao Yang District will provide late-phase clinical trial services, including site management , biostatistics, data management, medical writing and regulatory affairs support.

General manager Vincent Yen said the office  “will leverage QPS’ quality and training systems to offer customized, high-quality drug development solutions best suited for local Chinese biopharma, as well as global biopharma’s local affiliates​.”

QPS has been building is presence in Asia since even before it acquired a majority stake in Qualitix Clinical Research in March last year​. The process began in January 2011 when it invested in Indian bioanalytical services firm Bioserve Clinical Research​.

The following month QPS bought the Taiwan Center of Toxicology’s preclinical services unit​.

Related topics: Clinical Development, Phase III-IV

Related news

Show more

Related products


Lyophilization Scale-Up and Tech Transfer

Baxter BioPharma Solutions | 12-Mar-2018 | Technical / White Paper

There are few challenges when increasing the scale of production for a solution formulation, but the challenges drastically increase when the formulation...

Leveraging Best Practices in Primary Packaging

Leveraging Best Practices in Primary Packaging

Catalent Pharma Solutions | 05-Mar-2018 | Technical / White Paper

When planning a clinical trial, overlooking the importance of primary packaging can be a mistake. From stability concerns to labeling to patient compliance...


Process Development for Lyophilized Products

Baxter BioPharma Solutions | 30-Oct-2017 | Application Note

Baxter approaches formulation and process development with the intention of identifying the failure points for the product. Knowing where the product fails...


Advancing therapeutics for myeloma

Recipharm AB | 04-Sep-2017 | Case Study

Multiple myeloma is the second most common blood cancer in the world and despite survival rates increasing over the last decade, there remains a requirement...

Related suppliers